$0.75
-0.03(-3.34%)
Mkt Cap $15M
$0.39
$1.46
52-Week Range
At a Glance
AI-generatedTalphera, Inc.
8-K
Talphera, Inc. issued a press release announcing fourth quarter and full year 2025 financial results, including Q4 net loss of $3.8 million ($0.06 per share), full year net loss of $14.3 million ($0.34 per share), and cash and investments of $20.4 million as of December 31, 2025. The company reported 50% enrollment in the NEPHRO CRRT study, closure of a $4.1 million financing tranche, and 2026 cash operating expenses guidance of $17-18 million excluding stock-based compensation.$15M
Market Cap
$13.5K
Revenue
-$7M
Net Income
Employees13
Fundamentals
How The Business Makes Money
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
Industry Drug Manufacturers - Specialty & Generic
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001427925
ISINUS00444T2096
Phone650 216 3500
Address1850 Gateway Drive, San Mateo, CA, 94404, US
SEC EDGAR